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Effect of Chlorhexidine/Silver Sulfadiazine-Impregnated
Central Venous Catheters in an Intensive Care Unit with
a Low Blood Stream Infection Rate after Implementation
of an Educational Program: A Before–After Trial*
DOUGLAS J.E. SCHUERER,1 JEANNE E. ZACK,2 JAMES THOMAS,3 INGRID B. BORECKI,4
CARRIE S. SONA,3 MARILYN E. SCHALLOM,3 MELISSA VENKER,2
JENNIFER L. NEMETH,3 MYRNA R. WARD,3 LINDA VERJAN,3 DAVID K. WARREN,5
VICTORIA J. FRASER,5 JOHN E. MAZUSKI,1 WALTER A. BOYLE,6
TIMOTHY G. BUCHMAN,1 and CRAIG M. COOPERSMITH1

ABSTRACT
Background: Current guidelines recommend using antiseptic- or antibiotic-impregnated central venous catheters (CVCs) if, following a comprehensive strategy to prevent catheter-related blood stream infection (CR-BSI), infection rates remain above institutional goals based
on benchmark values. The purpose of this study was to determine if chlorhexidine/silver sulfadiazine-impregnated CVCs could decrease the CR-BSI rate in an intensive care unit (ICU)
with a low baseline infection rate.
Methods: Pre-intervention and post-intervention observational study in a 24-bed surgical/trauma/burn ICU from October, 2002 to August, 2005. All patients requiring CVC placement after March, 2004 had a chlorhexidine/silver sulfadiazine-impregnated catheter inserted
(post-intervention period).
Results: Twenty-three CR-BSIs occurred in 6,960 catheter days (3.3 per 1,000 catheter days)
during the 17-month control period. After introduction of chlorhexidine/silver sulfadiazineimpregnated catheters, 16 CR-BSIs occurred in 7,732 catheter days (2.1 per 1,000 catheter days;
p  0.16). The average length of time required for an infection to become established after
catheterization was similar in the two groups (8.4 vs. 8.6 days; p  0.85). Chlorhexidine/silver
sulfadiazine-impregnated catheters did not result in a statistically significant change in the
microbiological profile of CR-BSIs, nor did they increase the incidence of resistant organisms.
Conclusions: Although chlorhexidine/silver sulfadiazine-impregnated catheters are useful
in specific patient populations, they did not result in a statistically significant decrease in the
CR-BSI rate in this study, beyond what was achieved with education alone.

*Some of the material contained herein was presented orally (no written abstract) at the 35th Critical Care Congress,
Society of Critical Care Medicine, San Francisco, January 23, 2006.
Departments of 1Surgery, 4Genetics, 5Internal Medicine, and 6Anesthesiology, Washington University School of
Medicine, St. Louis, Missouri.
Departments of 2Hospital Epidemiology and Infection Control and 3Nursing Barnes-Jewish Hospital, St. Louis,
Missouri.
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U.S. CENTERS FOR DISEASE CONTROL AND
PREVENTION (CDC) estimate that 250,000
catheter-related blood stream infections (CRBSIs) occur annually in the United States [1],
although the incidence of this complication differs among countries [2]. The mortality rate of
CR-BSI is controversial, with estimates ranging
from 0 to 35% [3–8]. Although the attributable
mortality rate of a CR-BSI is unclear, these infections place a substantial burden on the
health care system, because they increase
length of stay [4,6–8] and have been estimated
to cost as much as $56,167 (in 1998 dollars) in
an intensive care unit (ICU) patient [9].
Exposure to central venous catheters (CVCs)
is common in ICU patients, with utilization
rates ranging from 0.36 CVC days/total patient
days in coronary care units to 0.83 CVC
days/total patient days in cardiothoracic ICUs.
Surgical and medical ICUs have rates of 0.63
and 0.52, respectively [10]. Despite the high rate
of CVC utilization in ICUs, multiple studies
have shown that most CR-BSIs are preventable,
if not all. One successful strategy is the implementation of an educational program aimed at
physicians, nurses, or the entire multidisciplinary ICU team [11–16]. These programs typically stress adherence to best-practice behaviors known to prevent CR-BSIs, including the
use of full barrier precautions [17], 2%
chlorhexidine skin preparation at the insertion
site [18], appropriate hand hygiene [19,20], and
specifying the anatomic site of CVC placement
(preferably the subclavian vein, then internal
jugular, lastly femoral vein) [21–23]. Whereas
the decrease in CR-BSIs varies depending on
which intervention is being studied, a recent
study by Berenholtz et al. demonstrated almost
complete elimination of CR-BSIs from a surgical ICU after initiation of a comprehensive prevention program [24].
Another tool to prevent CR-BSIs is the use
of antiseptic- or antimicrobial-impregnated
catheters. To date, there have been 19 randomized trials, three meta-analyses, and two
cost-benefit analyses of the efficacy of either
chlorhexidine/silver sulfadiazine- or minocycline/rifampin-impregnated catheters [25]. The
majority of these studies demonstrated significant decreases in CR-BSI rates without the development of resistant organisms, regardless of
HE

which catheter was used [26,27]. Of note, placement of antiseptic-impregnated catheters is effective in decreasing CR-BSI if evidence-based
practices are adhered to, but infection rates are
still higher than desired [28]. The accumulated
weight of these studies has resulted in recommendations from the CDC [1], the Agency for
Healthcare Research and Quality [29], and
thought leaders in the field [30,31] to use antiseptic- or antimicrobial-impregnated catheters
in select patient populations, although the efficacy of these devices has not been accepted universally [32].
Because antiseptic- or antimicrobial-impregnated catheters are more expensive than standard CVCs, but the attributable cost of an infection is much greater than the cost of a
catheter, there has been substantial interest in
determining at-risk populations that would
benefit most from the use of these catheters.
The CDC recommends that an antiseptic- or antimicrobial-impregnated CVC be placed “in
adults whose catheter is expected to remain in
place 5 days if, after implementing a comprehensive strategy to reduce rates of CR-BSI,
the CR-BSI rate remains above the goal set by
the individual institution based on benchmark
rates and local factors” [1]. “Comprehensive
strategy” is defined as an educational program
directed toward those who insert and maintain
CVCs, as well as usage of both maximum barrier precautions and 2% chlorhexidine for skin
preparation for CVC insertion.
Few data exist currently on the efficacy of antiseptic- or antimicrobial-impregnated catheters
in ICUs that have instituted the comprehensive
strategy outlined by the CDC. The purpose of
this study was to address that specific question—
what is the utility of antiseptic- or antibioticimpregnated catheters (specifically chlorhexidine/silver sulfadiazine-impregnated catheters)
in an ICU with low infection rates after a successful educational program to prevent CR-BSI?
Previously, we instituted educational and behavioral interventions designed to prevent CRBSI [11,12], resulting in infection rates that were
one-third the United States national average, as
determined by the National Nosocomial Infections Surveillance (NNIS) system at the time of
publication. To determine if there was additional efficacy in using chlorhexidine/silver
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sulfadiazine-impregnated catheters despite our
low CR-BSI rates, we studied the effect of inserting these catheters in all patients in our surgical ICU over an 18-month time span.

PATIENTS AND METHODS
Study location and patient population
Barnes-Jewish Hospital is a 1,344-bed tertiary-care, university-affiliated teaching hospital. All patients admitted to the surgical ICU
between October 1, 2002, and August 31, 2005,
were enrolled in the study. The surgical ICU
admits all critically ill non-cardiothoracic and
non-neurosurgical surgical and trauma patients. Between October, 2002 and March, 2003,
the surgical ICU had 18 beds. After a threemonth transition, when the number of beds
was variable, the surgical ICU expanded to 24
beds in May, 2003. This is reflected in an increase in yearly admissions from 1,499 in 2003
to 1,636 in 2004. The average length of stay was
constant throughout the study at 4.3 days, as
were nursing staff ratios. Throughout the
study, all patients admitted to the surgical ICU
were followed prospectively by an infection
control team and surveyed for blood stream infections. Data for this study were collected after completion of our published educational
and behavioral interventions to prevent CR-BSI
in the surgical ICU [11,12].
Demographic data (age, CVC duration,
Acute Physiology and Chronic Health Evaluation [APACHE] II score, ICU and hospital
length of stay, CVC insertion site) were retrieved from the Project IMPACT database
(Cerner, Inc., Kansas City, MO). Demographic
data from a patient were recorded only once,
regardless of how many CVCs were inserted.
Prior to March 2004, this database was incomplete for most months. Thus, the demographic
data presented in the pre-intervention group
that did not have routine placement of
chlorhexidine/silver
sulfadiazine-impregnated catheters consist of data from only three
non-contiguous months. To determine whether
the patient population in the surgical ICU
changed over the course of the study, demographic data from patients admitted before
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March, 2004 (pre-intervention) were compared
and found to be similar to both the post-intervention group from March, 2004–August, 2005
(where data were collected on all patients for
18 months) and all admissions to the surgical
ICU for a six-month period earlier in 2002 (data
not shown).
Each infection was classified as primary or
secondary according to the CDC definitions
used in previous publications on CR-BSI from
our institution. A CR-BSI was defined as (1) a
pathogen isolated from blood culture not related to infection at another site; or (2) fever
38.5°C, chills, or hypotension and either of
the following: (a) A common skin contaminant
isolated from two blood cultures drawn on separate occasions unrelated to infection at another site; or (b) a common skin contaminant
isolated from a blood culture from a patient
with a CVC for which the physician initiated
antimicrobial therapy.
Updates on CR-BSI rates were reported
monthly at the surgical ICU’s quality improvement conference and were compared
with both prior rates within the surgical ICU
and the published NNIS rates. The study was
approved by the Washington University
School of Medicine Human Studies Committee,
and informed consent was waived.
Study design
Patients admitted to the surgical ICU prior to
March 2004 (pre-intervention group) had conventional CVCs placed. Although chlorhexidine/silver sulfadiazine-impregnated catheters
have been available commercially for years,
they were not available in the ICU during the
pre-intervention period in accordance with
hospital policy at the time. All patients admitted to the surgical ICU after March, 2004 who
required CVC insertion had chlorhexidine/silver sulfadiazine-impregnated catheters (Arrowgard Blue Plus; Arrow International, Reading, PA) placed (post-intervention group, with
the intervention defined as the placement of
chlorhexidine/silver sulfadiazine-impregnated
catheters in patients who required a CVC).
These second-generation catheters have both
external coating and internal impregnation.
The fact that all patients received these
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catheters was based on a decision that any CVC
placed in the surgical ICU was likely to stay in
place for five days, and therefore met the CDC
criteria for placement of antiseptic-impregnated catheters. Of note, mandatory educational modules on how to prevent CR-BSI continued on a regular basis throughout the study
for both physicians and nurses in the surgical
ICU.
A pre-hoc decision was made that the primary endpoint would be CR-BSI rates for CVCs
placed in the surgical ICU, whereas the CR-BSI
rate for all CVCs was a secondary endpoint regardless of whether they were placed inside or
outside the surgical ICU. The rationale behind
this decision was to eliminate the confounding
effect of non-impregnated CVCs placed in the
operating room, emergency department, hospital wards, interventional radiology department, or another hospital in the primary analysis. When examining the secondary endpoint
of CR-BSI rates regardless of where a CVC was
placed, a potential confounder was that some
CVCs were placed immediately prior to a patient’s admission (in the operating room),
whereas some (e.g., Hohn catheters; Bard Access Systems, Salt Lake City, UT) were placed
weeks or months earlier. Because there was no
way of knowing how long every one these devices had been in place, catheter days for all
lines were calculated by convention, assuming
they were placed on admission to the surgical
ICU. The calculated CR-BSI rates presented for
all CVCs therefore likely represent overestimates of the true infection rate. The CR-BSI
rates were calculated as infections/1,000
catheter days for the duration of the study.
Each day a patient had a CVC in place was
counted as a catheter day, regardless of the
number of CVCs a patient had at a given time
(i.e., the small minority of patients with multiple catheters in place simultaneously was
counted daily as representing one catheter
day).
All CVCs placed in the surgical ICU throughout the study were inserted by residents, fellows, two full-time nurse practitioners, or attending physicians. The residents were from
the departments of surgery (post-graduate year
[PGY]-1 and -2), anesthesiology (PGY-1–3), or
emergency medicine (PGY-2) during their sur-
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gical ICU rotation. All procedures were supervised by surgery, anesthesiology, or pulmonary/critical care fellows or by the attending physicians (50% each from the departments
of surgery or anesthesiology). Peripherally inserted catheters and arterial catheters were excluded from study analysis.
On the basis of the results in the pre-intervention group, described below, the study was
powered to determine if antiseptic-impregnated catheters would result in a 60% decrease
in CR-BSI (i.e., similar to that achieved with education alone) [11]. This was done using a base
frequency of 0.00330 (23/6,960), an alpha of
0.05, 80% power, and an expected post-intervention group of 7,000 catheter days. With a
one-tailed test, statistical significance would be
demonstrated if the number of infections decreased to 9.
Statistical analysis
Data were analyzed using the statistical software program Prism 3.0 (GraphPad Software,
San Diego, CA). Infection rates and contingency tables (i.e., when comparing insertion
site in the pre- and post-intervention groups)
were analyzed using the chi-square test. Demographic and microbiology comparisons between the pre- and post-intervention groups
were performed using the Mann-Whitney Utest. An alpha 0.05 was considered statistically significant.

RESULTS
Patients
There were 4,630 patients admitted to the
surgical ICU during the 35 months of the
study: 2,079 in the 17 months from October,
2002 to February, 2004 (prior to the institution
of chlorhexidine/silver sulfadiazine-impregnated catheters) and 2,551 in the 18 months
from March 2004 to August 2005 (when all patients receiving a CVC had an antiseptic-impregnated catheter inserted). Throughout the
study, slightly more than one-third of all CVCs
were placed in the surgical ICU, whereas the
remainder were inserted in other locations
(e.g., operating room, emergency department,
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interventional radiology department). Demographics were similar in the pre-intervention
and post–intervention groups except for a
slightly higher APACHE II score in the postintervention group (Table 1). The majority of
CVCs were placed in the internal jugular vein,
but this was attributable predominantly to
placement of CVCs in the operating room
(where insertion was nearly exclusively in the
internal jugular); the majority of CVCs inserted
in the surgical ICU were placed in the subclavian vein (data not shown). Of note, simply
having a CVC in place was a marker of illness
severity throughout the study because patients
who had a CVC had higher mean APACHE II
scores (18.2 vs. 15.6) and longer mean lengths
of stay (6.9  1.1 vs. 4.3  7.2 days) than those
without CVCs.
Catheter-related BSI in CVCs placed
in surgical ICU
An average of 49 CVCs were placed per
month in the surgical ICU throughout the
study (range 15 to 64). There were 23 CR-BSIs
in 6,960 catheter days of CVCs placed in the
surgical ICU in the pre-intervention group (3.3
per 1,000 catheter days). After the introduction
of chlorhexidine/silver sulfadiazine-impregnated catheters, there were 16 CR-BSIs in 7,732
days (2.1 per 1,000 catheter days; p  0.16).
When examined over six-month increments,

TABLE 1.

DEMOGRAPHICS

Where catheter placed (%)
In surgical ICU
Outside surgical ICU
Age (years)
Mean catheter duration (days)
7 days (%)
7–10 days (%)
10 days (%)
Mean APACHE II score
Mean ICU length of stay (days)
Mean hospital length of stay (days)
Insertion site (%)
Subclavian vein
Internal jugular vein
Femoral vein
aBased

OF
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the infection rates were variable throughout the
study (Table 2).
The demographics of the patients who developed CR-BSI in CVCs placed in the surgical
ICU were similar regardless of whether the infection was of a standard catheter or a chlorhexidine/silver sulfadiazine-impregnated catheter
(Table 3). Length of stay and anatomic site of
catheter insertion also were similar. The average length of time a surgical ICU-placed CVC
was indwelling prior to the development of
CR-BSI was more than eight days, which is substantially greater than the average length of
time the “typical” CVC remained in place, considering that fewer than 20% of all CVCs were
indwelling for longer than seven days (compare length of catheterization for all CVCs in
Table 1 with the duration of catheterization in
CVCs that became infected in Table 3). No statistically significant differences in microbial
isolates were noted in infections of CVCs
placed in the surgical ICU, regardless of
whether the patient had a standard catheter or
a chlorhexidine/silver sulfadiazine-impregnated catheter, with gram-positive organisms
predominating in both groups (Table 4).
Catheter-related BSI in all CVCs
In addition to these infections of CVCs placed
in the surgical ICU, there were six CR-BSIs in
CVCs placed prior to patient arrival in the sur-

PATIENTS

WITH

CENTRAL VENOUS CATHETER

Pre-interventiona

Post-interventionb

34.0
66.0
60.4  0.7
2.8  1.0
83.0
12.1
4.9
17.1  1.2
7.0  0.8
25.6  2.9

39.0
61.0
58.9  2.5
3.6  0.7
82.8
11.9
5.3
18.2  0.6
6.9  1.1
26.6  7.3

35.5
57.3
7.2

39.3
52.6
8.1

0.56

on sampling of three months on 161 patients.
 1,480 patients.
ICU  intensive care unit; APACHE  Acute Physiology and Chronic Health Evaluation.

bN

P value

0.35
0.12

0.04
0.87
0.83
0.85
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TABLE 2. CR-BSI RATES

AT

SIX-MONTH INTERVALS

OF

CENTRAL VENOUS CATHETERS PLACED

IN

SURGICAL ICU

Primary
infections

CVC days

Infections/1,000 CVC days

4
11
8

2,343
2,470
2,147

1.7
4.4
3.7

3.3

2
5
9

2,578
2,402
2,752

0.8
2.1
3.3

2.1

Pre-intervention
October, 2002–March, 2003
April, 2003–September, 2003
October, 2003–February, 2004a
Post-intervention
March, 2004–August, 2004
September, 2004–February, 2005
March, 2005–August, 2005

Total rate for period:
infections/1,000 CVC days

aFive-month interval.
CR-BSI  catheter-related blood stream infection; CVC  central venous catheter.

gical ICU in both the pre- and post-intervention
groups. Among all CVCs, there were 29 infections in the pre-intervention group (4.2 per 1,000
catheter days) and 22 infections in the post-intervention group (2.7 per 1,000 catheter days, p 
0.15), including 16 of chlorhexidine/silver sulfadiazine-impregnated catheters placed in the surgical ICU and six of standard catheters placed
elsewhere. By comparison, in 2004, the NNIS
rate for surgical ICUs nationwide was 3.4 per
1,000 catheter days. At all times during the
study, the CR-BSI rates were lower than the
NNIS rates published for that year, despite the
fact that NNIS rates have declined steadily over
the past three years [10,33]. Of note, the rate of
secondary blood stream infections did not
change throughout the study, with 28 secondary BSIs in both the pre-intervention and
post-intervention time periods.

DISCUSSION
This study demonstrates that placing
chlorhexidine/silver sulfadiazine-impregnated
TABLE 3.

catheters in all surgical ICU patients requiring
CVC insertion failed to result in a statistically
significant decrease in CR-BSI rates below the
already-low rates obtained as the result of a
comprehensive educational program and adherence to best-practice behaviors. Despite examining a number of infection-related parameters and having more than 600 CVCs placed
in each group, chlorhexidine/silver sulfadiazine-impregnated catheters had no statistically significant impact on any endpoint examined.
There is little question that antiseptic- or antibiotic-impregnated catheters can prevent infection when used in the proper circumstances,
because the preponderance of published literature on the subject supports their use. As such,
our data do not refute the CDC recommendation to use these catheters when a CVC is expected to be in place for five days, CR-BSI rates
are above an institutional goal despite an educational program, and both maximum barrier
precautions and 2% chlorhexidine skin preparation are used. What is unclear from the CDC
recommendation is what constitutes an appro-

DEMOGRAPHICS OF PATIENTS HAVING CATHETER-RELATED BLOOD STREAM INFECTIONS
CENTRAL VENOUS CATHETERS PLACED IN SURGICAL INTENSIVE CARE UNIT

FROM

Mean age (years)
Male (%)
Mean catheter time prior
to infection (days)
Insertion site (%)
Subclavian vein
Internal jugular vein
Femoral vein

Pre-intervention

Post-intervention

P value

55.5  17.5
13 (56.0)
8.4  2.9

55.2  20.0
9 (56.0)
8.6  3.2

0.97
1.00
0.70

17 (73.9)
5 (21.8)
1 ( 4.3)

8 (50.0)
8 (50.0)
0 (50.0)

0.14
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TABLE 4. MICROORGANISMS ISOLATED FROM PATIENTS WITH CATHETER-RELATED BLOOD STREAM
INFECTIONS FROM CENTRAL VENOUS CATHETERS PLACED IN SURGICAL INTENSIVE CARE UNIT

Gram-positive bacteria
Coagulase-negative staphylococci
Enterococcus faecalis
Enterococcus faecium (vancomycin-resistant)
Staphylococcus aureus (methicillin-resistant)
Gram-negative bacteria
Acinetobacter baumannii
Pseudomonas aeruginosa
Enterobacter cloacae
Serratia marcescens
Yeast
Aspergillus spp.
Candida albicans
Candida parapsilosis

priate institutional goal. In light of the fact that
published data indicate that CR-BSI can be
eliminated, we made the determination that the
goal infection rate for the surgical ICU at
Barnes-Jewish Hospital should be zero. Thus,
strict implementation of the CDC guidelines
would result in our using antiseptic- or antibiotic-impregnated catheters (either chlorhexidine/silver sulfadiazine or minocycline/rifampin) for all patients expected to have a
catheter in place longer than five days. However, our results do not provide compelling evidence to justify placing chlorhexidine/silver
sulfadiazine-impregnated catheters, although
we cannot determine if minocycline/rifampinimpregnated catheters would have yielded
similar results, nor can we rule out a true difference with chlorhexidine/silver sulfadiazine
catheters that this study was not powered to
detect.
The demographics of all patients with CVCs
were strikingly similar throughout the 35
months of the study, as were the characteristics
of the patients whose catheters became infected,
regardless of whether the devices were chlorhexidine/silver sulfadiazine-impregnated. One interesting note was the non-significant trend toward more episodes of fungemia after the
institution of chlorhexidine/silver sulfadiazineimpregnated catheters. Whereas numerous
studies have demonstrated no change in infection patterns after the introduction of antisepticor antimicrobial-impregnated catheters, combining the data contained herein with those from

Pre-intervention (%)

Post-intervention (%)

17 (73.9)
7
7
2
1
5 (21.8)
4
1
0
0
1 ( 4.3)
1
0
0

8 (50)
3
3
2
0
4 (25)
1
1
1
1
4 (25)
0
3
1

previous studies from our surgical ICU identified two episodes of fungemia over 56 months
prior to the usage of chlorhexidine/silver sulfadiazine-impregnated catheters compared with
four in the subsequent 18 months. Longer-term
follow-up would be needed to determine the
veracity of this finding, which still would not
prove causality.
This study has a number of limitations. The
first is simply our conclusion that there is no
benefit in using chlorhexidine/silver sulfadiazine-impregnated catheters in an ICU where
infection rates already are low following an educational program and compliance with bestpractice behaviors. Despite there being 800 additional catheter days in the post-intervention
group, there were seven fewer infections, a 30%
decrease in the rate of BSI. Our conclusion of
non-significance is based solely on the pre-determined establishment of an alpha of 0.05.
Because our previous educational program decreased CR-BSI rates more than 70%, we powered this study to detect a similar decrease
in infections, not a 30% decrease. Clearly, if
chlorhexidine/silver sulfadiazine-impregnated
catheters actually decrease CR-BSI rates by
30%, this would be both biologically meaningful and cost-effective, even though it would not
have been identified by the present study. With
our low baseline BSI rate, a power analysis indicates that more than 35,000 catheter days
would have been required in both the pre-intervention and the post-intervention groups to
demonstrate a decrease of 30% in the CR-BSI
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rate. Such power is not feasible in a single-institution study. Because the study was designed
to only look for a major decrease in CR-BSI, it
is possible that it fails to recognize the significance of a more modest decrease in infection
rates, even if one is truly present. The substantial variability of our infection rates from
month to month (Table 2), although we minimized this variability as much as possible by
comparing aggregate data from 17 months preintervention and 18 months post-intervention,
means that observation over a different time
period might have yielded a different result.
Other limitations exist in the study design.
Compared with a randomized trial, a pre/post
study is susceptible to temporal bias attributable to unrecognized changes in patient populations or ICU practices. This study also could
have been biased toward the intervention
group, because there was no blinding to the use
of the chlorhexidine/silver sulfadiazine-impregnated catheters. Further, we made the a priori decision that all CVCs placed in the surgical ICU had a substantial chance of being in
place for five days to meet the CDC recommendation for antiseptic or antimicrobial
catheter placement. However, the data presented in Table 1 demonstrate that more than
80% of the CVCs in the surgical ICU were in
place for fewer than seven days. This discrepancy is not as great as it might seem, because
the majority of CVCs were placed outside the
surgical ICU, and these were likely to be in
place for a shorter time than catheters placed in
the surgical ICU because CVCs placed in the
emergency department are considered contaminated by convention and are removed within
24–48 h, whereas catheters placed in the operating room frequently are intended for intra-operative monitoring and are removed shortly after surgery if no major complications occur. In
contrast, CVCs placed in the surgical ICU generally are placed because long-term (e.g., parenteral nutrition) or reliable access (e.g., vasopressor therapy, determination of intravascular
volume status) is needed, which makes it more
likely that a CVC placed in the surgical ICU will
be present for longer than five days. Nonetheless, some unknown percentage of CVCs placed
in the surgical ICU during this study were likely
to have been removed within five days, which
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could confound our results. This difference in
duration depending on where a catheter was
placed (e.g., emergency department, surgical
ICU) likely explains why more than 60% of the
CVCs were placed outside the surgical ICU and
yet infections in these non-antibiotic-impregnated catheters made up only a small percentage of the overall CR-BSI in both the pre-intervention and the post-intervention group. The
lack of demographic data for 14 of 17 months
in the pre-intervention group also is a limitation. Although the demographic data for three
non-contiguous months were similar to those
for the post-intervention group (and to those
from the six months prior to the start of this
study), we cannot rule out a transient change in
patient population in 2003 that could have affected the results of this study. It is important
to note that whereas some demographic data
are missing for the pre-intervention group, the
infection data were obtained using a different
database and reflect accurately all 4,630 patients
and 14,692 catheter days throughout the duration of the study.
A final limitation is the catheter used.
Whereas there are substantial data supporting
the benefit of chlorhexidine/silver-sulfadiazine-impregnated catheters [34–36], there also
are studies that do not demonstrate a significant decrease in CR-BSI with their usage
[37–39]. Because minocycline/rifampin-impregnated catheters have been shown to be superior to first-generation chlorhexidine/silver
sulfadiazine-impregnated catheters [40], it is
possible that different results would have been
obtained had we used minocycline/rifampinimpregnated catheters.
Despite these limitations, this study has important implications for ICUs that have been
successful in decreasing CR-BSI rates below
NNIS averages, but have been unable to bring
their rates to zero. In the subset of ICUs that
have CR-BSI rates below the NNIS rate, our
data indicate that inserting chlorhexidine/silver sulfadiazine-impregnated catheters in all
patients does not result in a significant decrease
in infections (the study was not powered to
demonstrate a smaller effect). Additional studies are needed in different ICUs and with different catheters to determine the generalizability of these findings.
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